AAD House Call: ARQ-151 for Chronic Plaque Psoriasis

March 21, 2020
Kevin Kunzmann

Lisa Stein Gold, MD, of Henry Ford Hospital discusses promising phase 2 data for a new PDE4 inhibitor.

Late-breaking data originally planned for presentation the American Academy of Dermatology (AAD) 2020 Scientific Sessions—which has since been cancelled due to concerns raised by the coronavirus (COVID-19) pandemic—show greater potential for investigational drug ARQ-151 (roflumilast cream) as a treatment for chronic plaque psoriasis.

The phase 2b findings, gathered by Linda Stein Gold, MD, of the Henry Ford Hospital, and colleagues, compliment a growing portfolio for the PDE4 inhibitor as a potential treatment for inflammation-based, chronic skin diseases.

In a special edition House Call video interview with HCPLive®, Stein Gold discussed the new findings and what future benefit the topical therapy may have for dermatology.